参考文献(向下滑动) [1] Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood. 1997;89(6):2079-2088. [2] Greenberg PL, Tuechler H, Schanz J, et al. Revised in...
1.MDS prognosis: Outlook and life expectancy.Medical News Today.com 2.Valent, Orazi A.et al.Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.Oncotarget. 2017 Jul 5;8(43):73483-73500. 3. How I use molecular genetic tests to evaluate pat...
参考文献: 1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood,1997,89:2079–2088. 2.Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross...
What is my prognosis? How do I find a doctor who specializes in MDS? Are there any other medical providers I might need to see? Are there other factors that could affect my treatment and prognosis? You will also want to ask questions to help you decide on the right treatment plan, such...
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia- Manero G, Sole F, Bennett JM, et al. Revised interna- tional prognostic scoring system for myelodysplastic syndromes. Blood...
MDS patients with relapse after HCT become often refractory to treatment, or are not fit enough to be treated. The main risk factors for treatment response are time from transplantation to relapse and percentage of marrow blast with better prognosis in patients who have only a molecular relapse....
Patients with “higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor prognosis because of a high risk of progression to secondary acute myeloid leukemia with low chemosensitivity. Allogeneic hematopoietic stem cell transplantation remains the only treatment that offers ...
et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997). Article CAS PubMed Google Scholar Agarwal, A. et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and ...
Assessment of prognosis is of paramount importance in heterogeneous MDS. Insights in pathophysiological mechanisms and development of investigational tools has brought forward a high number of features with a possible use as prognostic factors in this disease. After theoretical considerations on prognosis an...
Other prognostic factors Age is an import dicator of poor prognosis; however, Prognostic factors it is not luded in the original or revised IPSS because it International prognostic scoring system (IPSS) and its could allow underestimation of the severity of update myelodys stic syndromes in young...